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Abstract 
This study was designed to explore the placebo-controlled effects of risperidone on cognitive-motor 
processes, dyskinetic movements, and behavior in children receiving maintenance risperidone therapy. 
Sixteen children aged 4-14 years with disruptive behavior were randomly assigned to drug order in a 
crossover study of risperidone and placebo for 2 weeks each. Dependent measures included tests of sustained 
attention, memory, visual matching, tremor, seat activity, abnormal movements, and parent behavior ratings. 
Results were compared by repeated measures ANOVA Fourteen boys and 2 girls with disruptive behavior 
and IQ ≤ 84 all completed the protocol. Risperidone was superior to placebo on response time (p = 0.01, ηP2 = 
0.43) and seat movement (p < 0.05, ηP2 = 0.29) on a short-term memory task, and on a measure of static tremor 
(p = 0.05, ηP2 = 0.28). There was not a significant difference between treatment conditions on the Abnormal 
Involuntary Movement scale. Risperidone was superior to placebo on three subscales of the Nisonger Child 
Behavior Rating Form [Overly Sensitive (p < 0.01, ηP2 = 0.44), Conduct Problem (p = 0.02, ηP2 = 0.36), 
Hyperactivity (p = 0.03, ηP2 = 0.32)] and on the Hyperactivity/Noncompliance subscale of the Aberrant 
Behavior Checklist (p = 0.01, ηP2 = 0.41). Significant increases in heart rate (p = 0.05, ηP2 = 0.27) and weight (p 
= 0.02, ηP2 = 0.36) occurred in the risperidone condition. The findings suggest a beneficial effect of 
risperidone after several months of treatment on efficiency of responding, activity level, static tremor, and 
aspects of behavior. 
1. Introduction 
Antipsychotics are commonly used for managing certain psychiatric disorders that occur in 
childhood: schizophrenia, autistic disorder, delusional manic-depressive disorder, and bipolar 
disorder (Botteron & Geller, 1998). Antipsychotics have also occasionally been used to manage 
disruptive behavior disorders [i.e., attention deficit hyperactivity disorder (ADHD), oppositional 
defiant disorder (ODD), and conduct disorder (CD)] when more conventional treatments, such as 
psychostimulants and tricyclic antidepressants have failed (Aman, De Smedt, Derivan, Lyons, & 
Findling, 2002; Gunther, Herpertz-Dahlman, Jolles, & Konrad, 2006). The efficacy of risperidone 
for treating aggression, self-injury, and tantrums has been established in children with autistic 
disorder (Research Units on Pediatric Psychopharmocology Autism Network, 2002). Despite a 
helpful role for the antipsychotic medications in many childhood conditions, there is a persistent 
although poorly substantiated impression that these medicines cause ‘‘cognitive blunting’’ in 
children. This may be more commonly heard than seen in print, but we believe that it is the cause 
of considerable resistance to antipsychotic treatment by physicians and nonmedical professionals 
alike. 
At the same time, the limited data regarding cognitive blunting by antipsychotic medicines 
is largely negative and frequently badly out of date (see Ernst et al., 1999; Aman, 1984; Aman, 
Marks, Turbott, Wilsher, & Werry, 1991). There are good theoretical reasons to believe that novel 
antipsychotics may have no effects on cognition or may actually enhance cognitive functioning. 
The basis for this belief comes from research in schizophrenia, Alzheimer’s disease, and in 
children with disruptive behavior disorder (DBD). 
The therapeutic effects of classical antipsychotic medication in treatment of the positive 
symptoms of schizophrenia are thought to be due to the ability of these drugs selectively to block 
post-synaptic dopamine D2 receptors and thereby reduce dopaminergic transmission (Stip, 
Chouinard, & Boulay, 2005; Honey et al., 1999). 
The novel antipsychotic agents have a greater affinity for serotonin 5-HT2 receptors than 
D2 receptors and have been effective in the treatment of both positive and negative symptoms of 
schizophrenia, including cognitive impairment. Over the last several years, studies have shown 
significantly improved cognitive performance in schizophrenic patients taking novel 
antipsychotics in comparison to those taking high-potency classical antipsychotics or no treatment 
(Bilder et al., 2002; Purdon et al., 2000; Keefe, Silva, Perkins, & Lieberman, 1999). In one study, 
investigators found that switching patients from classical to novel antipsychotics improved 
cognitive functioning (Mori, Nagao, Yamashita, Morinobu, & Yamawaki, 2004). In other 
comparative studies novel antipsychotics showed improvements over classical antipsychotics in 
the areas of attention, verbal working memory, executive function, and in visuomotor tasks 
(Cuesta, Paealta, & Zarzuela, 2001; Honey et al., 1999; Green et al., 2000; Gallhofer, Bauer, Lis, 
Krieger, & Gruppe, 1996). 
However, not all studies have shown an advantage of the novel antipsychotics over the 
more classical drugs. Geddes, Freemantle, Harrison, and Bebbington (2000), conducted a 
meta-regression analysis and controlled for medication doses that were higher than the 
recommended dose of classical antipsychotics used in some trials. They reported only a modest 
advantage of the atypical antipsychotics in extrapyramidal symptoms over the classical drugs, and 
the efficacy and tolerability advantage had all but disappeared. Although they did not specifically 
measure cognitive function, that report suggests that at least some benefits of atypical 
antipsychotics may be due to higher doses of classical drugs. 
Recently, researchers have investigated the therapeutic effects of novel antipsychotics in 
children with DBD’s (e.g., Aman et al., 2002; Snyder et al., 2002). Investigators assessed 
cognitive function, and they found that there was either no change or beneficial effects (i.e., verbal 
memory, short-term memory, and attention) with the use of novel antipsychotics (Pandina et al., 
2007; Troost et al., 2006; Gunther et al., 2006; MacQueen & Young, 2003; Borison, 1996; 
Meltzer, 1995). 
Another concern in using antipsychotic medicines with young people is the possibility that 
they may cause withdrawal or tardive dyskinesia. However, available data on the novel 
antipsychotics suggests that they may be safer than classical antipsychotics in this respect, 
especially when taken in small doses. Risperidone is a benzisoxazole derivative with high affinity 
for the serotonin 5-HT2A and dopamine D2 receptors and a 5-HT2A/D2 affinity ratio of 8:1. 
Risperidone also binds with moderate to high affinity to the α 1- and α2-adrenoreceptors, D1, D3, 
and D4 receptors, and histamine H1 receptors (Toren, Ratner, Laor, & Weizman, 2004). 
The present study was designed to test whether risperidone has an effect on 
cognitive-motor performance as compared with placebo. Our hypotheses were: (a) that risperidone 
would have no adverse effects on cognitive-motor performance in children who received 
maintenance therapy of risperidone for 4–20 months and (b) that children tested during the placebo 
phase would show no more dyskinetic movements than during risperidone treatment (i.e., there 
would be no unmasking of tardive dyskinesia). A secondary aim was to monitor behavioral 
changes as these children proceeded through the crossover trial. 
2. Methods and materials 
2.1. Participants 
The participants were 16 children and adolescents ages 4-14 years inclusive with an IQ ≤ 
84 who were recruited from two sources. The first group (n = 12) comprised children who took 
part in studies of risperidone efficacy in conduct disorder and oppositional defiant disorder. All of 
these children were initially selected for the presence of oppositional defiant disorder (ODD) or 
conduct disorder (CD). They were initially enrolled in an acute, 6-week, placebo-controlled trial 
(Aman et al., 2002) and then maintained on risperidone for 48 weeks (Findling et al., 2004). The 
second group comprised 4 children who had been medicated and maintained on risperidone by 
their physicians and who had a diagnosis of autistic disorder or pervasive developmental disorder 
not otherwise specified. Inclusion criteria were availability of a reliable informant, and good 
physical health as determined by history and physical examination. Exclusion criteria were: 
presence of psychosis, history of neuroleptic malignant syndrome (NMS), history of severe drug 
allergy or hypersensitivity, a medical disease such as heart disease, hypertension, liver or renal 
failure, known seizure disorder, or pregnancy. Of the 16 participants, 5 took psychostimulants (see 
Table 1, sample characteristics). In order to increase sample 
Age, year, mean ± S.D. 8.56 ± 2.6
Weight (kg), mean ± S.D. 52.54 ± 6.9
Height (in.), mean ± S.D. 78.14 ±45.1
Sex 
Male, no. (%) 14 (87.5)
Female, no (%) 2 (12.5)
Race 
White, no. (%) 13 (81.2)
Black, no. (%) 3 (18.8)
DSM-IV axis I diagnosis 
Attention deficit hyperactivity disorder (ADHD) no. (%) 1 (6.2)
ADHD plus conduct disorder (CD) no. (%) 2 (12.5)
ADHD plus oppositional defiant disorder (ODD) no. (%) 6 (37.5)
CD no. (%) 1 (6.3)
ODD, no. (%) 3 (18.7)
DSM-IV axis II diagnosis 
Autism spectrum disorder (ASD) 3 (18.7)
Intellectual functioning 
Average intellectual functioning, no. (%) 1 (6.3)
Borderline intellectual disability, no. (%) 10 (62.5)
Mild intellectual disability, no. (%) 4 (25.0)
Moderate intellectual disability, no. (%) 1 (6.2)
IQ, mean ± S.D. 71.81 ± 13.4
Daily dose risperidone, mean ± S.D. 1.65 ±1.3
Stable concomitant med at BL; total, no. (%) 5 (32.0)
Table 1 Sample characteristics (N = 16) size, exclusion criteria were relaxed, and the final subject enrolled 
received pre-established clonidine and lithium with risperidone. All concomitant medications remained 
constant throughout the trial. 
2.2. Study design 
This was a double-blind, placebo-controlled, crossover study in which subjects were 
randomized to drug order. Assignment to drug order was stratified by age (4–9 years and 10–14 
years). Each condition lasted 2 weeks. Half of the participants were assigned to a placebo (PBO)–
risperidone (RIS) sequence and the remainder to a RIS–PBO sequence. Participants received the 
drug and placebo conditions for 2 weeks each. For the children identified in the community and 
taking risperidone at the direction of their physicians, participation followed approval by their 
physicians to take part. 
The O.S.U. Institutional Review Board approved the study. After the study was explained 
to each participant and his or her guardian or legal representative, the participant’s guardian or 
legal representative provided written informed consent. 
3. Procedure 
All participants were assessed with an IQ test [Stanford-Binet Intelligence Scale IV ed. 
(Thorndike, Hagen, & Sattler, 1986); Wechsler Intelligence Scale for Children, 3rd ed.(Wechsler, 
1991); Kaufman Brief Intelligence Test (Kaufman & Kaufman, 1990)]. Clinical and cognitive 
assessments were carried out at baseline, week 3, and week 5, of each condition. We endeavored to 
standardize the time of day for the assessments, although a few subjects were not able to arrive at 
exactly the same time throughout the trial. 
3.1. Dosing and dosing schedule 
Risperidone tablets were supplied by Janssen Pharmaceutica as matching placebo and 
risperidone tablets in doses of 0.25, 0.50, and 1.00 mg. All children were assessed three times: (a) 
during a screen visit, while taking their usual dose of risperidone; (b) 2 weeks later, while 
randomly assigned to risperidone or placebo, and (c) 2 weeks later while assigned to the alternative 
drug condition. Participants receiving the RIS–RIS–PBO sequence were given their usual dose of 
risperidone at baseline and in weeks 2 and 3. Then in week 4 the risperidone was terminated and 
placebo was provided. For participants receiving the RIS–PBO–RIS sequence, following week 3, 
the placebo condition was terminated and risperidone was titrated over the first 6 days of week 4. 
The third assessment took place at the end of week 5, when participants assigned to RIS–PBO–RIS 
sequence were at their full dose for 8 days. 
3.2. Cognitive-motor measures 
Cognitive-motor performance was assessed using three attentional / memory tasks and a 
measure of fine motor ability designed for children with intellectual disability or pervasive 
developmental disorder (Aman, 1991). All were controlled by computer, and seat activity was 
measured unobtrusively throughout each of the cognitive tasks. 
The first cognitive test was a titrated delayed Matching-to-Sample (MTS) task (Aman, 
Kern, McGhee, & Arnold, 1993). This test measures memory for colors. The child was shown a 
color (red, yellow, or blue) at the center-top of the screen and the child depressed the window 
where the color appeared (observing response). One second later, the colors red, yellow, and blue 
were presented at the bottom of the screen. The child’s task was to decide which color matched the 
preceding color and to press the corresponding window. Every time the child made three 
consecutive correct responses, one second was added to the delay between the stimulus and the test 
colors. Whenever the child responded incorrectly, 1 s was subtracted from the delay (down to a 
minimum of 1 s). Dependent measures included mean accuracy, response time, longest delay 
achieved, and mean delay (s). 
The second cognitive test was a Short Term Recognition Memory (STRM) task (Aman, 
1991; Sprague & Sleator, 1977). In this task, the participants were required to look at arrays of 3 or 
9 cartoon pictures and to try to remember them. After each array was presented, there was a 4-s 
delay. Then the child was presented with a single picture and s/he had to decide whether that was a 
member of the preceding array (indicated by pressing a ‘‘Same’’ or ‘‘Different’’ switch). Two 
dependent measures were recorded, mean accuracy and mean response time. 
The third task was a Continuous Performance Task (Aman, 1991). In this task, the 
participant was told to watch a screen on which pictures of a witch and Snow White were 
presented over time. Participants were asked to respond by pressing a lever whenever they saw the 
witch and to refrain from responding when Snow White appeared. Dependent variables included 
errors of omission (failures to detect the witch), errors of commission (responses to Snow White), 
and mean response time. 
Seat activity was measured while the participants were being tested on the above tasks, 
using a ‘‘wiggle’’ seat developed by Sprague and Toppe (1966). The platform of the seat had a 
pivot under its center with microswitches under each of the sides. A slight tilt of the seat activated 
a microswitch, and activity was recorded cumulatively by the computer. 
Finally, the Graduated Holes Task (Kløve, 1963), consisted of a metal plate with several 
holes drilled in it. The child was told to hold a metal stylus at arm’s length in the center of each 
hole, without touching the sides, for 10 s. This was done for the five largest holes and for each hand 
separately. The number of contacts and the time of contact between the stylus and the metal plate 
were electronically recorded. 
3.3. Clinical measures 
Parents rated the children on two standardized checklists. The Nisonger Child Behavior 
Rating Form (NCBRF) is an informant behavior rating scale developed for assessing children and 
adolescents with developmental disabilities Aman, Tasse, Rojahn, and Hammer (1995). The 
NCBRF consists of six problem behavior subscales designated as Conduct Problem, 
Insecure/Anxious, Hyperactivity, Self-Injury/Stereotypy, Self-Isolated/Ritualistic, and Overly 
Sensitive. The Aberrant Behavior Checklist (ABC) is another widely used rating scale for 
assessing behavior problems in subjects with developmental disabilities (Aman, Singh, Stewart, & 
Field, 1985a, 1985b; Aman & Singh, 1994). The ABC subscales are labeled as Irritability, 
Lethargy/Social Withdrawal, Stereotypic Behavior, Hyperactivity, and Inappropriate Speech. 
3.4. Safety measures 
Safety measures included physician assessments of vital signs, weight, adverse events 
(AEs), and concomitant medication. In addition to spontaneously reported AEs, potential 
dyskinetic movements were assessed using the Abnormal Involuntary Movement Scale (AIMS). 
This 12-item scale was developed by the Psychopharmacology Research Branch of NIMH 
(NIMH, 1985). 
4. Statistical analysis 
Two separate analyses were conducted using the General Linear Models package in SPSS. 
A mixed ANOVA was conducted to assess whether there were study by drug condition differences 
in parent ratings and test scores. This was done to determine if the responses of the four children 
recruited in the community differed from those who were initially in the DBD studies. Next, 
interval-level data were analyzed as a function of Drug Order (PBO-RIS vs. RIS-PBO) and Drug 
(PBO vs. RIS). Only data from assessment sessions 2 and 3 were used for the analyses (i.e., the 
screen was used solely for training purposes). Effect sizes (partial eta squared, ηP2) were provided 
in addition to p-values; they can be informative when power is low due to small sample sizes. In all 
tests, p-values ≤ 0.05 were used to indicate statistical significance. 
5. Results 
5.1. Subjects 
The intent-to-treat analysis included all 16 participants However, the analyses were run 
with and without the data of one boy for the following reasons: (a) the shelf-life for active 
medicine expired before he took the study medicine (this is the only subject for whom this 
occurred); (b) his behavior deteriorated precipitously on active medication (we suspected, but 
could not prove, that drug conditions were inadvertently reversed); (c) this was the only subject to 
lose weight on putative active medication, again supporting our belief that the conditions may have 
been reversed. The parent of one child discontinued his medicine in the last treatment phase 
‘‘because it did not work.’’ This child was tested, as scheduled and his data were retained. 
5.2. Exposure to study medication 
The mean dose of risperidone was 1.65 mg/day (S.D. = 1.25) (dose range = 0.38–5.0 
mg/per day). The child taking 5.0 mg/day was recruited from the community for the second cohort. 
5.3. Study by drug interactions 
A Mixed ANOVA was conducted to assess whether there were between group differences 
(cohort 1 vs. cohort 2) in test scores and parent ratings. Study by drug interactions were significant 
for two variables. Two of the study participants who were randomized to the RIS–RIS–PBO 
sequence scored positive for dyskinesia on the AIMS while in the placebo phase of the study. 
Also, there was a significant difference between the two study samples on parent reported 
stereotypic behavior. Not surprisingly, children in the second cohort (who had PDDs) scored 
significantly higher on the Stereotypic Behavior subscale of the ABC than children in the first 
cohort (who had no PDDs). As there were no differences between groups in terms of their drug 
responses, we combined them for all subsequent analyses. 
5.4. Efficacy measures 
Table 2 shows the outcome means and standard deviations for Drug Order A (RIS–PBO) 
and Drug Order B (PBO–RIS) on the cognitive-motor measures. Results indicate three significant 
main effects of drug condition. Compared to placebo, risperidone resulted in faster response times 
[F(1,12) = 9.20, 
Cognitive-motor tasks, N = 15 Cognitive-motor outcomes   Drug condition effects 
 Drug order A, N = 9 Drug order B, N = 6 F p ߟ௉ଶ  
 Time 1—RIS Time 2—PBO Time 2—RIS Time 1—PBO    
 (mean) (mean) (mean) (mean)    
Match-to-Sample task (MTS)        
Accuracy 84.87 81.79 89.35 93.05 0.004 0.95 0.00
Response time 1.72 1.91 1.77 1.74 0.19 0.67 0.01
Longest delay 7.22 6.89 8.00 9.33 0.25 0.62 0.02
Mean delay 3.91 3.49 4.48 4.80 0.008 0.93 0.00
1 
Seat movements 82.67 95.11 130.50 184.00 1.78 0.21 0.12
Short Term Recognition Memory task (STRM)†       
Accuracy 73.44 67.71 65.97 72.22 0.003 0.96 0.00
Response time 2.66 3.19 1.85 2.16 9.20 0.01 0.43
Seat movements 104.75 169.25 170.00 312.00 4.87 0.05 0.29
Continuous Performance Task (CPT)†       
Omissions 1.75 1.75 1.83 1.66 0.03 0.86 0.00
3 
Commissions 2.38 3.88 2.83 4.00 1.73 0.21 0.13
Response time (RT) 0.56 0.61 0.51 0.46 0.001 0.98 0.00
Seat movement 198.75 287.63 303.00 427.67 0.80 0.38 0.06
Graduated Holes Task (GHT)        
Contacts 230.63 278.00 232.83 282.17 4.95 0.05 0.29
Error time 13.24 19.46 14.32 14.64 1.96 0.19 0.14
† Sample size = 14 because 2 subjects did not master the task. 
Table 2 Cognitive-motor effects of risperidone (one subject deleted) 
Scales/physiological Behavioral/physiological outcomes  Drug condition effects 
outcomes, N = 15 Treatment condition 1, N = 9 Treatment condition 2, N = 
6 
F p ߟ୔ଶ 
 Time 1—RIS Time 
2—PBO 
Time 2—RIS Time 
2—PBO 
   
 (mean) (mean) (mean) (mean)    
Nisonger Child behavior Rating Form (NCBRF)       
Conduct Problems 19.11 22.89 18.17 31.00 7.34 *0.02 0.36 
Insecurity 10.67 12.22 11.67 17.17 3.77 0.07 0.23 
Hyperactivity 11.67 14.56 11.17 15.50 6.04 *0.03 0.32 
Self-injury 0.78 1.33 0.50 0.67 2.70 0.13 0.17 
Ritualistic 3.11 3.22 1.67 2.67 0.51 0.49 0.04 
Overly sensitive 5.89 8.00 4.00 7.50 10.35 **0.007 0.44 
Aberrant Behavior Checklist (ABC)        
Irritability 16.44 19.33 15.33 22.83 3.18 0.07 0.23 
Lethargy 5.44 4.44 4.50 6.00 0.02 0.88 0.00 
Stereotypic behavior 1.33 2.67 0.33 1.50 1.44 0.25 0.10 
Inappropriate speech 4.11 3.78 3.50 4.67 0.80 0.39 0.06 
Hyperactivity/noncompliance 19.11 26.56 21.33 32.50 8.93 *0.01 0.41 
Physiological outcomes        
Systolic BP 101.56 101.22 103.00 98.67 0.93 0.35 0.07 
Diastolic BP 67.11 68.78 70.33 69.00 0.006 0.94 0.00 
Heart rate (BPM) 95.00 80.67 93.50 88.83 4.81 0.05 0.27 
Weight (lbs) 82.46 80.31 81.42 79.92 7.40 *0.02 0.36 
* p ≤ 0.05. 
** p ≤ 0.01. 
Table 3 Effects of risperidone on behavior, vital signs, and weight (one subject deleted) 
p = 0.01, ߟ௉ଶ  = 0.43] and fewer seat movements [F(1,12) = 4.87, p = 0.048, ߟ௉ଶ  = 0.29] on the 
STRM task and fewer contacts (less tremor) on the Graduated Holes Task [F(1,12) = 4.95, p = 
0.046, ߟ௉ଶ  = 0.29]. 
Table 3 shows the outcome means for drug condition on the NCBRF, ABC, and safety 
outcomes. Results indicate significant main effects of drug on 3 subscales of the NCBRF, with 
risperidone superior to placebo on Conduct Problem [F(1,13) = 7.34, p = 0.02, ߟ௉ଶ  = 0.36], 
Hyperactivity [F(1,13) = 6.04, p = 0.03, ߟ௉ଶ  = 0.32], and Overly Sensitive [F(1,13) = 10.35, p = 
0.01, ߟ௉ଶ  = 0.44]. Risperidone was also shown to be superior to placebo on the ABC 
Hyperactivity/Noncompliance subscale [F(1,13) = 8.93, p = 0.01, ߟ௉ଶ  = 0.41]. Heart rate (BPM) 
increased significantly during the risperidone phase when compared to placebo [F(1,13) = 4.81, p 
= 0.05, ߟ௉ଶ  = 0.27], as did weight gain (lbs) [F(1,13) = 7.40, p = 0.02, ߟ௉ଶ  = 0.36]. 
6. Discussion 
6.1. Cognitive-motor effects 
The present analysis addressed cognitive functioning because this is a domain that has 
received very little attention in children thus far. No declines in measures of attention (e.g., CPT) 
and working memory (e.g., Match-to-Sample Task) occurred with risperidone. On the contrary, 
there was significant improvement in response time on the Short Term Memory task for the 
risperidone condition. In addition, there was significant improvement in the number of seat 
movements on the Short Term Memory task, indicating decreased motility in the risperidone 
condition. Finally, on the measure of motor steadiness (i.e., Graduated Holes Task), the 
risperidone condition caused a significant decrease in the number of contacts, suggesting 
improved motor control compared with placebo. 
Somnolence is a frequent side effect of atypical antipsychotics early in treatment, causing 
many professionals to wonder if this would result in impaired learning. However, one detailed 
analysis of a large sample of children with autism indicated that reports of somnolence usually 
ceased within 2 weeks of the last dose titration of risperidone (Aman et al., 2005). Most of the 
participants in the current trial had either a disruptive behavior disorder or autism, and it is 
reasonable, therefore, to hypothesize that risperidone may have reduced behaviors incompatible 
with learning performance, such as stereotypy or hyperactivity. 
There is minimal literature on the effects of atypical antipsychotics on cognition in children 
and adolescents, forcing us to inspect the literature from adult trials (specifically in patients with 
schizophrenia). Purdon (1999) did an early analysis of the literature with atypical antipsychotics 
and reported enhancement of verbal fluency and learning, visuomotor tracking, and visual and 
verbal attention. Stip et al. (2005) analyzed 26 studies involving classical and atypical 
antipsychotic effects on cognitive-motor functioning in schizophrenic adults. (a) Motor 
performance findings: For risperidone, they noted one positive and two negative trials. In the case 
of other atypical antipsychotics (clozapine, olanzapine, quetiapine), they noted four instances of 
improvement and four cases of no change on tests of motor performance. (b) Attentional findings: 
Stip et al. (2005) located four risperidone trials showing significant improvement in attention and 
three trials that showed no change. For clozapine, they reported three trials of improved attentional 
performance, two showing no change, and reduced performance was noted in one other 
investigation. One trial of quetiapine showed significant improvement in attention during the acute 
trial, but at follow-up there was no change. (c) Memory findings: Stip et al. reported one trial 
showing improvement and another showing no change with risperidone; one trial with clozapine 
showed improved performance while four others showed no changes on memory tasks. Keefe et 
al. (1999) conducted a rigorous review of atypical antipsychotic drug effects in patients with 
schizophrenia, totaling 15 studies. Among the investigations that were properly controlled, Keefe 
et al. reported improvements in attention, in executive function, and in visuospatial analysis. Both 
Purdon (1999) and Keefe et al. (1999) lamented the lack of placebo controls, the lack of blindness, 
uncertainty about medication status at baseline, and occasionally the lack of any baseline measures 
on the outcome variables. 
We were able to locate only three reports of the effects of risperidone (or any atypical 
antipsychotic) in children. Troost et al. (2006) assessed 24 children with pervasive developmental 
disorders and disruptive behavior who were clinical responders to risperidone in an open-label 
trial. All participants were randomized to a discontinuation study in which they received either 
risperidone maintenance or placebo substitution. On a divided attention task (which involved 
serial search in working memory), children assigned to placebo showed significant deterioration in 
performance, whereas those maintained on risperidone continued to improve. On a second task of 
‘‘focused attention’’ (requiring the classification of stimuli by their position) there were no 
drug-related changes. Günther, Herpertz-Daahl, Jolles, and Konrad assessed the effects of 
risperidone in 23 children with ADHD on tests of sustained attention, divided attention, and the 
Go/No-Go paradigm. Drug effects were assessed by comparing all changes to the performance of a 
control group comprising age-and-IQ-matched normal controls. No medication effects were 
detected on any of the cognitive variables. Pandina et al. (2007) assessed verbal memory and 
sustained attention in children with disruptive behavior disorders. In this acute 6-week trial, there 
were no performance differences between children receiving placebo and those receiving 
risperidone. 
Hence, there are minimal studies that have collected cognitive data in children with which 
to compare our results. However, on balance it seems that our lack of effect on the Continuous 
Performance Task is consistent with the findings reported by Troost et al. (2006) and by Pandina et 
al. (2007). There is no literature on seat activity in the context of performing cognitive tasks, but 
the reductions seen here seem entirely consistent with clinical reports of reduced overactivity with 
risperidone treatment (e.g., Aman et al., 2002; Research Units on Pediatric Psychopharmacology 
Autism Network, 2002). On balance, the studies conducted with adults having schizophrenia 
showed very mixed results insofar as memory is concerned, whereas we were unable to 
demonstrate enhancement or worsening of memory performance. Finally, this trial showed a 
significant reduction in static tremor, and this is consistent with several adult trials that reported 
improvements in fine motor function and visuomotor tracking. 
6.2. Behavioral effects 
Risperidone treatment was associated with improvement on the Conduct Problem, 
Hyperactivity, and Overly Sensitive subscales of the NCBRF and the 
Hyperactivity/Noncompliance subscale of the ABC. Aman et al. (2002) also saw reductions on all 
of these subscales in children with disruptive behavior disorders, whereas Snyder et al. (2002) 
observed reductions in all except the Overly Sensitive subscale. In a sense, this is a form of internal 
validation, as the same behavioral changes (except for Overly Sensitive) were seen on the same 
subscales across all three studies. 
6.3. Physical measures 
We noted a significant difference in heart rate, with significantly higher pulse rate in the 
risperidone condition. Aman et al. (2005) conducted a thorough analysis of AEs and did not 
observe significant differences in heart rate activity for 101 subjects with autism in the initial 
RUPP risperidone study. However, the assessment of heart rate in the current investigation was 
highly standardized; these participants were more cooperative than the participants in the RUPP 
autism study, and the conditions of assessment (following a mandatory 4-min of rest while sitting) 
were quite rigorous. This leads us to believe that this is a robust finding. Heart rate increases have 
often been reported with risperidone and other atypical antipsychotics (Tandon, 2002; Stigler, 
Potenza, & McDougle (2001)). Consistent with the RUPP report and many other investigations 
(Aman et al., 2005; Martin et al., 2004), we observed significant increases in weight with 
risperidone. 
7. Limitations 
This modest study had a number of limitations. First, the sample was heterogeneous in that 
11 participants had disruptive behavior disorders, 1 had ADHD, and 3 had high-functioning 
autism. Second, the sample size of 16 was small, although the crossover design helped to mitigate 
this. Third, we had little clinical control over the community sample used to augment our initial 
disruptive behavior disorder sample. Their medication work-up may have been different, the target 
symptoms likely were different, and their clinical response may have been larger or smaller than 
the participants whom we treated. Finally, our decision to discard the data from the participant 
whose medication expired was somewhat ‘‘arbitrary,’’ although we believe that it was the correct 
decision. Conversely, the study had some unusual strengths as well. Foremost among these is the 
computer-controlled cognitive battery, which children generally enjoy and which has been shown 
to be drug sensitive in the past. Second, this study adds to a very small literature on the cognitive 
(and other) effects of risperidone in children. 
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